Table 1 Candidate CpG islands and their matched genes selected from the targeted bisulfite sequencing data of 90 CRC patients are listed, and information pertaining to the genomic and functional location of CpG islands and their adjacent gene name is provided.
From: Hypermethylation of PDX1, EN2, and MSX1 predicts the prognosis of colorectal cancer
CGI_location | CGI_info | Gene | 30%_Diff | McoM | McaM | (McaM-McoM) |
|---|---|---|---|---|---|---|
chr7:27147589–27148389 | intragenic | HOXA3 | 83.3% (75/90) | 29.0 | 78.7 | 49.7 |
chr7:27146069–27146600 | intragenic | HOXA3 | 82.2% (74/90) | 26.0 | 74.0 | 48.0 |
chr19:49669275–49669552 | intragenic | TRPM4 | 81.1% (73/90) | 24.2 | 73.7 | 49.5 |
chr2:54086776–54087266 | promoter | GPR75-ASB3 | 80% (72/90) | 23.9 | 74.3 | 50.3 |
chr1:200010625–200010832 | intragenic | NR5A2 | 78.9% (71/90) | 9.1 | 57.7 | 48.7 |
chr13:28498226–28499046 | intragenic | PDX1 | 72.2% (65/90) | 9.1 | 55.0 | 45.9 |
chr5:140857864–140858065 | intragenic | PCDHGA2 | 72.2% (65/90) | 17.3 | 62.8 | 45.5 |
chr7:27182613–27185562 | promoter | HOXA-AS3 | 71.1% (64/90) | 21.4 | 62.6 | 41.2 |
chr19:48918115–48918340 | intragenic | GRIN2D | 69.9% (58/83) | 10.7 | 53.1 | 46.2 |
chr5:140864527–140864748 | promoter | PCDHGA2 | 68.9% (62/90) | 9.1 | 52.3 | 43.1 |
chr5:134363092–134365146 | intragenic | PITX1 | 67.8% (61/90) | 21.5 | 59.8 | 38.3 |
chr7:158936507–158938492 | promoter | VIPR2 | 65.6% (59/90) | 12.4 | 50.1 | 37.7 |
chr6:62995855–62996228 | promoter | KHDRBS2 | 63.3% (57/90) | 11.7 | 51.3 | 39.6 |
chr6:10398573–10398812 | intragenic | TFAP2A | 63.3% (57/90) | 16.1 | 53.0 | 36.9 |
chr7:27143181–27143479 | intergenic | — | 63.3% (57/90) | 26.0 | 62.6 | 36.7 |
chr7:24323558–24325080 | promoter | NPY | 63.3% (57/90) | 16.5 | 52.7 | 36.2 |
chr8:97171805–97172022 | promoter | GDF6 | 63.3% (57/90) | 19.8 | 53.5 | 33.7 |
chr13:53313127–53314045 | promoter | CNMD | 62.2% (56/90) | 15.6 | 50.9 | 35.3 |
chrX:142721410–142722958 | promoter | SLITRK4 | 60.7% (54/89) | 19.2 | 54.8 | 35.5 |
chr7:155255098–155255311 | intragenic | EN2 | 60% (54/90) | 17.0 | 52.2 | 35.2 |
chr13:102568425–102569495 | promoter | FGF14 | 60% (54/90) | 15.6 | 50.6 | 35.0 |
chrX:66766037–66766279 | intragenic | AR | 58.9% (53/90) | 20.3 | 55.8 | 35.5 |
chr9:37002489–37002957 | promoter | PAX5 | 58.9% (53/90) | 22.1 | 56.3 | 34.1 |
chrX:101906001–101907017 | promoter | ARMCX5-GPRASP2 | 57.8% (52/90) | 21.6 | 58.2 | 36.6 |
chr4:111549879–111550203 | intragenic | PITX2 | 57.8% (52/90) | 22.9 | 53.7 | 30.8 |
chr4:4864456–4864834 | intragenic | MSX1 | 57.3% (51/89) | 29.7 | 64.3 | 35.3 |
chr8:72753874–72754755 | promoter | MSC | 56.7% (51/90) | 26.7 | 58.7 | 32.0 |
chr19:46915311–46915802 | intragenic | CCDC8 | 55.6% (50/90) | 17.7 | 52.1 | 34.5 |
chr8:130995921–130996149 | intragenic | FAM49B | 54.4% (49/90) | 20.9 | 53.1 | 32.1 |
chr2:98962873–98964187 | promoter | CNGA3 | 54.4% (49/90) | 19.6 | 51.7 | 32.1 |
chr2:5836068–5837643 | intragenic | SOX11 | 54.4% (49/90) | 20.8 | 51.7 | 30.9 |
chr11:65359292–65360328 | intragenic | EHBP1L1 | 53.3% (48/90) | 26.6 | 58.0 | 31.4 |
chr6:108495654–108495986 | intragenic | NR2E1 | 53.3% (48/90) | 21.5 | 52.0 | 30.5 |
chr1:120905971–120906396 | promoter | HIST2H2BA (H2BP1) | 53.3% (48/90) | 28.8 | 59.1 | 30.3 |
chr13:70681732–70682219 | promoter | KLHL1 | 50% (45/90) | 25.1 | 55.5 | 30.4 |
CGI_location | CGI_info | Gene | 30%_Diff | McoM | McaM | (McaM-McoM) |
chr16:87441387–87441671 | intragenic | ZCCHC14 | 78.9% (71/90) | 77.98 | 28.81 | −49.17 |
chr7:5342299–5342599 | intragenic | SLC29A4 | 77.8% (70/90) | 73.15 | 26.40 | −46.75 |
chr20:33762403–33762774 | intragenic | PROCR | 66.7% (60/90) | 68.94 | 29.90 | −39.04 |
chr1:235805318–235805771 | intragenic | GNG4 | 56.7% (51/90) | 62.69 | 29.03 | −33.66 |
chr2:233925091–233925318 | promoter | INPP5D | 57.8% (52/90) | 52.94 | 20.31 | −32.63 |
